Last 25 quarters of trend data · Healthcare · Drug Discovery Platforms
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 27.07 | 30.22 | 63.69 | 62.77 | 15.15 | 105.38 | 27.64 | 36.13 | 125.89 | 17.85 | 31.53 | 43.61 | 54.10 | 40.58 | 34.15 | 26.33 | 26.17 | 35.34 | 45.79 | 57.66 | 290.13 |
| — | -71.3% | +130.5% | +73.8% | -88.0% | +490.4% | -12.3% | -17.2% | +132.7% | -56.0% | -7.7% | +65.6% | +106.7% | +14.8% | -25.4% | -54.3% | -91.0% | -90.9% | -92.6% | — | — | |
| P/B Ratio | 1.39 | 2.48 | 2.14 | 1.59 | 1.90 | 2.08 | 2.30 | 2.28 | 2.20 | 3.55 | 3.11 | 5.87 | 4.96 | 3.74 | 3.21 | 2.97 | 2.95 | 4.76 | 3.20 | 2.48 | 5.34 |
| — | +18.8% | -7.0% | -30.5% | -13.2% | -41.3% | -26.1% | -61.1% | -55.7% | -5.2% | -3.1% | +97.4% | +68.3% | -21.3% | +0.1% | +20.0% | -44.9% | -26.7% | -66.5% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.18 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -62.0% | 45.9% | -49.8% | -93.0% | 24.4% | -471.8% | -5.5% | -48.0% | -183.6% | 53.7% | 36.1% | 17.2% | 7.0% | -7.7% | 14.8% | -2.6% | 20.7% | -18.0% | -85.9% | -47.2% | 100.0% |
| — | +109.7% | -799.5% | -93.5% | +113.3% | -978.9% | -115.3% | -378.8% | -2725.5% | +799.8% | +143.6% | +766.0% | -66.3% | +57.5% | +117.3% | +94.5% | -79.3% | -118.0% | -185.9% | -147.2% | 0.0% | |
| Operating Margin | -867.9% | -664.0% | -1759.7% | -1985.6% | -304.8% | -3327.6% | -922.5% | -1297.9% | -4073.8% | -377.1% | -698.0% | -714.1% | -931.2% | -985.4% | -741.8% | -575.8% | -445.9% | -479.4% | -864.9% | -1056.4% | -2598.4% |
| — | +80.0% | -90.8% | -53.0% | +92.5% | -782.4% | -32.2% | -81.7% | -337.5% | +61.7% | +5.9% | -24.0% | -108.8% | -105.6% | +14.2% | +45.5% | +82.8% | +74.2% | +47.2% | +13.4% | -159.1% | |
| Net Margin | -863.4% | -641.6% | -1708.0% | -1815.6% | -304.2% | -3135.3% | -899.8% | -1373.3% | -3966.0% | -366.8% | -677.2% | -677.3% | -875.3% | -920.8% | -696.5% | -538.4% | -420.4% | -463.1% | -856.7% | -1056.4% | -2597.3% |
| — | +79.5% | -89.8% | -32.2% | +92.3% | -754.7% | -32.9% | -102.8% | -353.1% | +60.2% | +2.8% | -25.8% | -108.2% | -98.8% | +18.7% | +49.0% | +83.8% | +75.6% | +50.7% | +14.0% | -157.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -59.5% | -13.1% | -13.5% | -10.9% | -9.9% | -16.5% | -18.6% | -20.6% | -22.9% | -17.3% | -19.8% | -21.1% | -20.6% | -20.5% | -17.1% | -14.3% | -13.2% | -14.6% | -14.1% | -10.8% | -11.4% |
| — | +20.8% | +27.2% | +47.0% | +56.7% | +4.3% | +6.3% | +2.7% | -11.2% | +15.9% | -16.0% | -48.2% | -56.8% | -40.1% | -21.2% | -32.1% | -15.7% | -91.7% | +33.5% | — | — | |
| ROA | -44.1% | -9.8% | -10.3% | -8.4% | -7.5% | -12.0% | -13.2% | -14.7% | -16.5% | -12.7% | -14.6% | -15.1% | -14.5% | -14.3% | -11.9% | -9.8% | -8.8% | -9.4% | -9.3% | -8.3% | -10.2% |
| — | +18.6% | +22.1% | +43.2% | +54.3% | +5.7% | +9.9% | +2.5% | -13.6% | +11.2% | -23.3% | -53.4% | -65.3% | -52.3% | -27.2% | -18.1% | +14.4% | -34.7% | -4.2% | +22.7% | -18.6% | |
| ROIC | -95.8% | -21.4% | -23.2% | -21.2% | -17.4% | -27.2% | -26.3% | -26.7% | -37.4% | -38.1% | -42.8% | -52.5% | -66.1% | -68.5% | -97.2% | — | — | -408.7% | -132.1% | -27.3% | -20.3% |
| — | +21.3% | +11.9% | +20.5% | +53.6% | +28.5% | +38.5% | +49.2% | +43.3% | +44.4% | +56.0% | — | — | +83.2% | +26.4% | — | — | -1282.1% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.08 | 0.07 | 0.07 | 0.07 | 0.08 | 0.10 | 0.10 | 0.10 | 0.17 | 0.15 | 0.13 | 0.11 | 0.12 | 0.11 | 0.12 | 0.10 | 0.13 | 0.12 | 0.11 | 0.02 |
| — | +4.8% | -29.4% | -29.0% | -34.2% | -54.5% | -37.7% | -21.7% | -4.1% | +47.0% | +36.3% | +3.0% | +4.1% | -12.6% | -8.1% | +16.8% | +396.6% | +1333.6% | +409.2% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.50 | 5.01 | 5.03 | 5.47 | 5.50 | 4.60 | 3.58 | 4.11 | 3.81 | 4.35 | 6.07 | 4.65 | 4.70 | 4.36 | 3.78 | 5.34 | 5.68 | 5.80 | 5.65 | 7.23 | 11.46 |
| — | +8.9% | +40.6% | +33.0% | +44.4% | +5.7% | -41.0% | -11.5% | -19.0% | -0.2% | +60.4% | -13.0% | -17.3% | -24.8% | -33.0% | -26.1% | -50.4% | -58.5% | -74.2% | -12.5% | -0.6% | |
| Quick Ratio | 5.50 | 5.01 | 5.03 | 5.47 | 5.50 | 4.60 | 3.58 | 4.11 | 3.81 | 4.35 | 6.07 | 4.65 | 4.70 | 4.36 | 3.78 | 5.34 | 5.68 | 5.80 | 5.65 | 7.23 | 11.46 |
| — | +8.9% | +40.6% | +33.0% | +44.4% | +5.7% | -41.0% | -11.5% | -19.0% | -0.2% | +60.4% | -13.0% | -17.3% | -24.8% | -33.0% | -26.1% | -50.4% | -58.5% | -74.2% | -12.5% | -0.6% | |
| Interest Coverage | -355.30 | -447.41 | -422.97 | -347.88 | — | -194.78 | -357.12 | -397.91 | -294.70 | -172.01 | -247.89 | -4606.60 | -3732.00 | -3719.68 | -2950.04 | -3437.26 | -4421.46 | -4648.62 | -4681.86 | -3997.50 | -32476.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RXRX stock.
Recursion Pharmaceuticals, Inc.'s current P/E is -4.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Recursion Pharmaceuticals, Inc.'s current operating margin is -867.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Recursion Pharmaceuticals, Inc.'s business trajectory between earnings reports.